Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

83.93 -1.06 (-1.25%)
Streaming Delayed Price Updated: 11:48 AM EDT, Aug 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis
Merck halts vibostolimab and favezelimab trials due to efficacy results, prioritizing its oncology pipeline while the FDA reviews RSV drug clesrovimab. 
Via Benzinga
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025. 
Via Investor's Business Daily
Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season
From Merck & Co., Inc.
Via Business Wire
Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab
From Merck & Co., Inc.
Via Business Wire
Uncovering Dividend Opportunities with NYSE:MRK.
Why MERCK & CO. INC. (NYSE:MRK) qualifies as a good dividend investing stock. 
Via Chartmill
NYSE:MRK stands out as a stock that provides good value for the fundamentals it showcases.
Despite its impressive fundamentals, MERCK & CO. INC. (NYSE:MRK) remains undervalued. 
Via Chartmill
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC
From Merck & Co., Inc. Merck
Via Business Wire
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 gene amplification. 
Via Benzinga
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck & Co Unusual Options Activity For December 02
 
Via Benzinga
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over
Via The Motley Fool
Topics Stocks
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results in ovarian cancer. 
Via Benzinga
LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Why NYSE:MRK provides a good dividend, while having solid fundamentals.
Why the dividend investor may take a look at MERCK & CO. INC. (NYSE:MRK). 
Via Chartmill
Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer
Merck's ovarian cancer trial met its primary endpoint, while lymphoma trial data set the Phase 3 dose for zilovertamab vedotin at 1.75 mg/kg. 
Via Benzinga
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
From Merck & Co., Inc.
Via Business Wire
2 Healthcare Dividend Stocks to Hold for the Long Haul
Via The Motley Fool
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday
Via The Motley Fool
Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults
From Merck & Co., Inc.
Via Business Wire
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable. 
Via The Motley Fool
3 Ultra-Cheap Dividend Stocks to Buy in December
Via The Motley Fool
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market. 
Via Benzinga
FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations
From Merck & Co., Inc.
Via Business Wire
The Smartest Dividend Stocks to Buy With $3,000 Right Now
They may not offer the very highest yields, but their dividends are built to last, and even grow. 
Via The Motley Fool
The Data Shows Three Market-Jolting Forces On The Move
What we saw in the inflation data, income and spending-related reports points to a couple of big moves we need to start making now. 
Via Talk Markets
Topics Economy Stocks / Equities
Merck to Participate in the Citi 2024 Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Why Is Merck Stock Trading Higher On Monday?
Merck's ZENITH trial shows Winrevair significantly lowers morbidity or mortality risk in PAH patients, building on earlier Phase 3 STELLAR results. 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.